Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 9801902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1466-609X (Electronic) Linking ISSN: 13648535 NLM ISO Abbreviation: Crit Care Subsets: MEDLINE
    • Publication Information:
      Publication: London, UK : BioMed Central Ltd
      Original Publication: London : Current Science Ltd, c1997-
    • Subject Terms:
      Intensive Care Units*; Anti-Bacterial Agents/*therapeutic use ; Cephalosporins/*therapeutic use ; Drug Resistance, Bacterial/*drug effects ; Escherichia coli/*drug effects; Anti-Bacterial Agents/pharmacology ; Bacteremia/drug therapy ; Cephalosporins/pharmacology ; Germany ; Humans ; Population Surveillance ; Practice Patterns, Physicians'/statistics & numerical data
    • Abstract:
      Introduction: The objective of the present study was to analyse secular trends in antibiotic consumption and resistance data from a network of 53 intensive care units (ICUs).
      Methods: The study involved prospective unit and laboratory-based surveillance in 53 German ICUs from 2001 through 2008. Data were calculated on the basis of proportions of nonduplicate resistant isolates, resistance densities (that is, the number of resistant isolates of a species per 1,000 patient-days) and an antimicrobial usage density (AD) expressed as daily defined doses (DDD) and normalised per 1,000 patient-days.
      Results: Total mean antibiotic use remained stable over time and amounted to 1,172 DDD/1,000 patient-days (range 531 to 2,471). Carbapenem use almost doubled to an AD of 151 in 2008. Significant increases were also calculated for quinolone (AD of 163 in 2008) and third-generation and fourth-generation cephalosporin use (AD of 117 in 2008). Aminoglycoside consumption decreased substantially (AD of 86 in 2001 and 24 in 2008). Resistance proportions were as follows in 2001 and 2008, respectively: methicillin-resistant Staphylococcus aureus (MRSA) 26% and 20% (P = 0.006; trend test showed a significant decrease), vancomycin-resistant enterococcus (VRE) faecium 2.3% and 8.2% (P = 0.008), third-generation cephalosporin (3GC)-resistant Escherichia. coli 1.2% and 19.7% (P < 0.001), 3GC-resistant Klebsiella pneumoniae 3.8% and 25.5% (P < 0.001), imipenem-resistant Acinetobacter baumannii 1.1% and 4.5% (P = 0.002), and imipenem-resistant K. pneumoniae 0.4% and 1.1%. The resistance densities did not change for MRSA but increased significantly for VRE faecium and 3GC-resistant E. coli and K. pneumoniae. In 2008, the resistance density for MRSA was 3.73, 0.48 for VRE, 1.39 for 3GC-resistant E. coli and 0.82 for K. pneumoniae.
      Conclusions: Although total antibiotic use did not change over time in German ICUs, carbapenem use doubled. This is probably due to the rise in 3GC-resistant E. coli and K. pneumoniae. Increased carbapenem consumption was associated with carbapenem-resistant K. pneumoniae carbapenemase-producing bacteria and imipenem-resistant A. baumannii.
    • Comments:
      Comment in: Crit Care. 2010;14(3):171. (PMID: 20587087)
    • References:
      J Antimicrob Chemother. 2010 Feb;65(2):233-8. (PMID: 19996144)
      J Antimicrob Chemother. 2006 Jul;58(1):159-67. (PMID: 16698845)
      Infection. 2010 Feb;38(1):19-24. (PMID: 19904488)
      Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S11-23. (PMID: 12516026)
      Lancet Infect Dis. 2009 Apr;9(4):228-36. (PMID: 19324295)
      Scand J Infect Dis. 2007;39(1):63-9. (PMID: 17366015)
      Emerg Infect Dis. 2002 Mar;8(3):278-82. (PMID: 11927025)
      Clin Infect Dis. 2005 May 15;40(10):e84-6. (PMID: 15844056)
      Br J Clin Pharmacol. 2006 May;61(5):585-91. (PMID: 16669851)
      Clin Infect Dis. 2009 Sep 1;49(5):682-90. (PMID: 19622043)
      Infect Control Hosp Epidemiol. 2006 Feb;27(2):146-54. (PMID: 16465631)
      J Clin Microbiol. 2004 Mar;42(3):1089-94. (PMID: 15004058)
      Gesundheitswesen. 2000 May;62(5):295-302. (PMID: 10893878)
      Infection. 2009 Aug;37(4):349-52. (PMID: 19277464)
      Infection. 2003 Aug;31(4):208-15. (PMID: 14562943)
      Infect Control Hosp Epidemiol. 2009 Jan;30(1):103-5. (PMID: 19067603)
      Emerg Infect Dis. 2007 Aug;13(8):1144-9. (PMID: 17953083)
      Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93. (PMID: 18068814)
      Intensive Care Med. 2009 Jan;35(1):91-100. (PMID: 18670757)
      J Antimicrob Chemother. 2009 Mar;63(3):609-14. (PMID: 19151036)
      Ann Clin Microbiol Antimicrob. 2004 Jul 29;3:14. (PMID: 15283864)
      J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i29-36. (PMID: 19675016)
      JAMA. 2003 Nov 19;290(19):2588-98. (PMID: 14625336)
      PLoS Med. 2006 Feb;3(2):e29. (PMID: 16398572)
      Intensive Care Med. 2009 May;35(5):862-70. (PMID: 19034426)
      J Antimicrob Chemother. 2008 Dec;62(6):1474-6. (PMID: 18794158)
      Expert Rev Anti Infect Ther. 2008 Oct;6(5):751-63. (PMID: 18847410)
      Antimicrob Agents Chemother. 2009 Oct;53(10):4511-3. (PMID: 19687250)
      J Antimicrob Chemother. 2007 Jun;59(6):1148-54. (PMID: 17434880)
      Acta Anaesthesiol Scand. 2007 Aug;51(7):937-41. (PMID: 17635399)
      J Clin Microbiol. 2009 Nov;47(11):3420-6. (PMID: 19726597)
      Lancet Infect Dis. 2008 Feb;8(2):125-32. (PMID: 18222163)
      J Antimicrob Chemother. 2009 Jun;63(6):1205-14. (PMID: 19329798)
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Cephalosporins)
    • Publication Date:
      Date Created: 20100616 Date Completed: 20110106 Latest Revision: 20220408
    • Publication Date:
      20221213
    • Accession Number:
      PMC2911759
    • Accession Number:
      10.1186/cc9062
    • Accession Number:
      20546564